Alfentanil potentiates anaesthetic and electroencephalographic responses to ketamine in the rat.
The interactions between mu-opioid and N-methyl-D-aspartate (NMDA) receptors have important implications for clinical pain management. We recently examined the pharmacokinetics of ketamine in rats following i.v. infusion of ketamine (racemate, 50 mg/kg/5 min) and found increased central nervous system distribution of ketamine in the presence of low constant plasma alfentanil concentrations (approximately 50 ng/ml). We now report on the effects of low plasma alfentanil concentrations on the duration of anaesthetic and electroencephalographic (EEG) responses to i.v. infusion of ketamine. Compared to ketamine alone, alfentanil significantly increased both the duration of anaesthesia (by 130%, P=0.00022) and the processed EEG power (microV(2)/s) (by 48%, P=0.0040). The plasma ketamine concentration producing half-maximal EEG effect was significantly reduced (by 60%, P<0.0001) in the presence of alfentanil. The results indicate that low plasma alfentanil concentrations potentiate the anaesthetic and EEG effects produced by ketamine.
Edwards
Stephen R
SR
Centre for Anaesthesia and Pain Management Research, University of Sydney at Royal North Shore Hospital, St. Leonard's NSW, 2065, Australia.
Mather
Laurence E
LE
D015760:Alfentanil / Q000494:pharmacology*; D000778:Anesthetics, Dissociative / Q000494:pharmacology*; D000818:Animals; D004357:Drug Synergism; D004569:Electroencephalography / Q000187:drug effects* / Q000379:methods; D007649:Ketamine / Q000097:blood / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D000778:Anesthetics, Dissociative; D015760:Alfentanil; D007649:Ketamine